Summary
Moderna's mRNA flu shot, mRNA-1010 (mFLUSIVA), has received FDA approval for adults aged 50 and up, marking the first mRNA flu vaccine to be approved. The approval follows a unanimous vote by FDA advisors and comes despite significant political challenges from anti-vaccine advocates.